XENICAL For Professionals For Consumers
SearchSitemapContact Us
Health Benefits of Weight Loss: Type 2 Diabetes

Weight loss improves health in patients with type 2 diabetes. It has been shown to “ameliorate insulin resistance, to improve carbohydrate tolerance and to reduce hyperglycemia and hyperinsulinemia.” 5

Published studies have shown that serum glucose levels began to improve within days after starting a weight-loss program – even on a moderately hypocaloric (1200 to 1500 calories/day) diet.48 Weight reduction in patients with type 2 diabetes also lead to increases in HDL cholesterol levels.5

XENICAL is indicated for obesity management in patients with an initial body mass index (BMI) of 30 or more and in patients with a BMI of 27 or more in the presence of other risk factors (e.g., hypertension, diabetes, dyslipidemia). After 6 months, 72% of patients lost 5% or more of their initial body weight, with a mean loss of 23 lbs. Weight loss has been shown to reduce or eliminate the need for diabetic drug therapy.47 It has also been demonstrated in a modest number of studies to improve abnormally low insulin sensitivity and coronary risk – promoting plasma lipoprotein levels found in obese subjects with the prediabetic condition known as syndrome X.21,22

Specific Health Benefits:

Population with Abnormal (Untreated) Risk Factors at Randomization

Weight Loss with XENICAL Plus Diet: Improved Fasting Insulin
  • In patients with abnormal baseline values of fasting insulin (>120 pmol/L), weight loss with XENICAL plus diet resulted in a greater decrease in fasting insulin than placebo (-39 pmol/L vs. –16 pmol/L, respectively) from randomization to 1 year.
Population as a Whole

XENICAL Plus Diet: Successful Weight Loss

In clinical trials involving 1064 patients, 69% on XENICAL plus diet lost 3% or more of initial body weight within 3 months, with a mean loss of 13 lbs.

The mean change in fasting insulin was –6.7 pmol/L for patients on XENICAL plus diet and +0.58 for patients on placebo plus diet.

In clinical trials, the overall mean weight loss from randomization to the end of 1 year in the intent-to-treat population was 13.4 lbs in patients treated with XENICAL plus diet versus 5.8 lbs in placebo-treated patients.

The long-term effects of orlistat on morbidity and mortality associated with obesity have not been established.

Managing Patients with Obesity-Related Comorbidities

More about Obesity as a Clinical Condition
Weight loss has been shown to reduce or eliminate the need for diabetic drug therapy.